Analysts expect the worldwide biosimilars market to reach approximately $35 billion by 2020! While developed markets remain important for biosimilars' manufacturers, Delloite analysis indicates that long term growth may be fueled by emerging markets. Therefore to remain competitive, manufacturers should develop a global biosimilars strategy that includes 'where to play' and 'how to win'.
Where to play?
To help biosimilars manufacturers understand which regions present the greatest potential for growth in the near and long term, Delloite evaluated the developed markets of the United States, EU5 and Japan, as well as emerging markets including BRICS (Brazil, Russia, India, China and South Africa) and MIST (Mexico, Indonesia, South Korea and Turkey) countries. The analysis focuses on six dimensions listed below.
Source: Secondary Research, Deloitte Subject Matter Advisors and Deloitte analysis in Winning with Biosimilars report, 2016
Where does China stand?
- In 2014, the draft on biosimilar guidelines was issued.
- Once a clear regulatory pathway for biosimilars is established, the market will be very attractive not only due to the volume potential but also the growing ability to pay.
- Similar to the tight controls requiring international companies to create partnerships or use domestic pharmaceutical distributors, the successful manufacturing and marketing of biosimilars will also require partnerships with domestic companies.
- There is still lack of physician trust and enthusiasm for non-branded drugs exacerbated by unsafe and counterfeit drugs.
Would you like to find out more? Read the full report here.
Published in: 2016